A fully human bispecific antibody against novel coronavirus variants

By integrating H4D12 and H4B6, the bispecific antibody of IgG-(scFv)2 form was solved, and the problem of weakening the effect of existing antibodies in the face of viral evolution and escape mutations is achieved, and a broad spectrum of a variety of new coronary mutations was achieved. Efficient and neutralizing improves the stability and economicality of treatment.

CN116891531BActive Publication Date: 2024-11-15ACADEMY OF MILITARY MEDICAL SCIENCES
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310790443.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-06-30
Publication Date
2024-11-15
Estimated Expiration
2043-06-30

AI Technical Summary

Technical Problem

The existing anti-novel coronavirus vaccines and neutralizing monoclonal antibodies are weakened in the face of continuous evolution and escape mutations of the virus, making it difficult to effectively resist a variety of submutants, resulting in increased treatment difficulty.

Method used

Develop a fully human bispecific antibody to build a bispecific antibody in the form of IgG-(scFv)2 by integrating the monoclonal antibodies H4D12 and H4B6 that have a strong neutralizing effect on the new coronavirus. and activity and antigen binding ability, reducing the probability of viral escape mutations.

Benefits of technology

It has achieved broad-spectrum and efficient neutralization activity for a variety of Omicron submutants and the new coronary bivariate strains that may appear in the future, which improves the effectiveness and stability of treatment, and reduces production costs and clinical development difficulties.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116891531B_ABST
    Figure CN116891531B_ABST
Patent Text Reader

Abstract

The present invention discloses a fully human bispecific neutralizing antibody that can resist the new coronavirus, which is modified from two fully human neutralizing antibodies of the new coronavirus. The antibody can effectively neutralize the currently popular Omicron subvariants BF.7, BA.5, XBB.1.5, BQ.1.1 and CH.1.1 with strong escape ability. Compared with the parent monoclonal antibody and cocktail strategy, the bispecific antibody disclosed in the present invention has stronger antiviral activity and the ability to inhibit escape mutations. It is a feasible and effective strategy for treating and preventing severe new coronavirus, and has the potential to become a candidate drug for intervention in the new coronavirus.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention discloses a bispecific antibody and belongs to the technical field of polypeptides. Background Art

[0002] The novel coronavirus is a single-stranded positive-sense RNA virus with an envelope. Its genome can mutate through a variety of mechanisms during replication, and its evolution rate is extremely fast. The Omicron variant continues to evolve, evolving into multiple subvariants such as BA.5, XBB, XBB.1.5, and BQ.1.1.

[0003] In the process of epidemic prevention and control, therapeutic antibody drugs have made important contributions. Monoclonal antibody drugs or cocktail therapies combined with monoclonal antibodies developed by large pharmaceutical companies such as Regeneron, Eli Lilly, GlaxoSmithKline, and AstraZeneca have been granted emergency use authorization by the US FDA for prevention and clinical treatment. However, the continuous adaptive evolution of the virus has weakened the efficacy of existing vaccines and evaded almost all developed neutralizing monoclonal antibodies. There is an urgent need to develop neutralizing antibody drugs that can provide protective effects.

[0004] Bispecific antibodies are a novel antibody drug model that integrates two specific antibodies into one molecule, showing unique properties different from single antibodies. Compared with single monoclonal antibodies, antibody cocktails and other strategies, bispecific antibodies have the following advantages: (1) Cocktail therapy requires the separate production of two antibodies, while bispecific antibodies only need to produce one, which has low production costs and is more convenient for preclinical and clinical development; (2) IgG-(scFv)2 bispecific antibodies have tetravalent antigen binding ability and improved neutralizing activity against viruses, especially the integration of two neutralizing antibodies with synergistic effects, whose neutralizing activity has a synergistic effect of "1+1>2"; (3) The combination of different binding epitopes of two monoclonal antibodies can tolerate more viral antigen site mutations and reduce the probability of viral escape mutations during treatment, which is of great significance for clinical treatment. Therefore, it is urgent to develop an economical and efficient bispecific antibody drug.

[0005] Bispecific antibodies do not exist in nature and can only be prepared artificially. After years of research and technological development, many different design strategies have emerged in the structure of bispecific antibodies. According to whether it contains the Fc functional region, it is mainly divided into two categories: full-length bispecific antibodies containing the Fc region and fragment bispecific antibodies without the Fc region. The characteristic of full-length bispecific antibodies is that the Fc region is retained, which can provide a longer half-life and stability in the body, and antibodies with Fc regions are easier to purify. In addition, the Fc region can mediate some immune-related functions, such as antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP) or complement-dependent cytotoxicity (CDC). Full-length bispecific antibodies containing Fc regions are in the form of Knobs-into-holes, Crossmab, DVD-Ig, IgG-(scFv)2, etc. Compared with traditional antibodies, fragment bispecific antibodies lack Fc and are relatively small in size, generally only 50 kDa, with better tissue permeability, and have certain advantages in the treatment of solid tumors. Currently, such bispecific antibodies mainly include bi-Nanobody, BiTE, DART, TandAbs, etc.

[0006] The purpose of the present invention is to construct a new bispecific antibody against the new coronavirus variants to cope with the persistent viral immune escape, and to provide candidate drugs for resisting the currently prevalent new coronavirus double variants with strong escape ability and those that may appear in the future. Summary of the invention

[0007] Based on the above-mentioned purpose, the present invention intends to construct a fully human bispecific antibody against novel coronavirus variants by using the screened monoclonal antibody H4D12 (Chinese patent application CN202211732654.4) which has a strong neutralizing effect on the wild type and Delta, BA.2, BA.2.75, BA.2.76 and other variants of the novel coronavirus, and the monoclonal antibody H4B6 (Chinese patent application CN202211734994.0) which has a strong neutralizing effect on the recently popular Omicron subvariants such as BA.5, BA.4.6, BF.7 as parent monoclonal antibodies on the basis of anti-novel coronavirus monoclonal antibodies.

[0008] The present invention first provides a fully human bispecific antibody against a novel coronavirus variant, wherein the bispecific antibody is composed of two polypeptide chains and two monoclonal antibody light chains, wherein the "polypeptide chain" is defined as a monoclonal antibody heavy chain and a single-chain antibody connected in series, wherein the monoclonal antibody heavy chain and the monoclonal antibody light chain are from the same parent monoclonal antibody, and in the bispecific antibody of the present invention, the monoclonal antibody heavy chain and the monoclonal antibody light chain from the same parent monoclonal antibody constitute the first antigen recognition region. The single-chain antibody described in the present invention refers to a monovalent antibody form connected in series by an antibody heavy chain variable region and a light chain variable region; in the bispecific antibody of the present invention, the single-chain antibody heavy chain variable region and the single-chain antibody light chain variable region constitute the second antigen recognition region; a complete bispecific antibody of the present invention includes two first antigen recognition regions and two second antigen recognition regions.

[0009] According to the technical solution provided by the present invention, the amino acid sequences of the variable regions CDR1, CDR2 and CDR3 of the heavy chain of the monoclonal antibody are shown as the amino acid sequences at positions 26-33, 51-57 and 96-106 of SEQ ID NO.1, respectively; the amino acid sequences of the variable regions CDR1, CDR2 and CDR3 of the light chain of the monoclonal antibody are shown as the amino acid sequences at positions 27-32, 50-52 and 89-97 of SEQ ID NO.3, respectively; the amino acid sequences of the variable regions CDR1, CDR2 and CDR3 of the heavy chain of the single-chain antibody are shown as the amino acid sequences at positions 487-494, 512-519 and 558-575 of SEQ ID NO.1, respectively; the amino acid sequences of the variable regions CDR1, CDR2 and CDR3 of the light chain of the single-chain antibody are shown as the amino acid sequences at positions 627-632, 650-652 and 689-696 of SEQ ID NO.1, respectively.

[0010] In the design scheme of the present invention, the monoclonal antibody heavy chain and the monoclonal antibody light chain are derived from the parent monoclonal antibody H4B6, constituting the first antigen recognition region of the bispecific antibody of the present invention. Therefore, in the present invention, the "monoclonal antibody heavy chain" refers to the heavy chain of the parent monoclonal antibody H4B6, and the "monoclonal antibody light chain" refers to the light chain of the parent monoclonal antibody H4B6. The single-chain antibody heavy chain variable region and the single-chain antibody light chain variable region are derived from the parent monoclonal antibody H4D12, constituting the second antigen recognition region of the bispecific antibody of the present invention. Therefore, in the present invention, the "single-chain antibody heavy chain" refers to the heavy chain of the parent monoclonal antibody H4D12, and the "single-chain antibody light chain" refers to the light chain of the parent monoclonal antibody H4D12. Previous studies have shown that both H4B6 and H4D12 recognize the RBD region of the new coronavirus. As taught by common technical knowledge in the art, the variable regions of the heavy and light chains of antibodies are responsible for binding to antigens, wherein the hypervariable regions of the variable regions (also known as the complementarity determining regions, CDRs, of antibody molecules) constitute the antigen binding sites of antibody molecules. In the technical scheme of the present invention, the bispecific antibody uses the above-mentioned four sets of CDR regions, i.e., the monoclonal antibody heavy chain variable regions CDR1, CDR2, CDR3 and the monoclonal antibody light chain variable regions CDR1, CDR2, CDR3 from H4B6 constitute the two first antigen recognition regions for recognizing the RBD region of the new coronavirus; the single-chain antibody heavy chain variable regions CDR1, CDR2, CDR3 and the single-chain antibody light chain variable regions CDR1, CDR2 and CDR3 from H4D12 constitute the two second antigen recognition regions for recognizing the RBD region of the new coronavirus.

[0011] In a preferred embodiment, the amino acid sequence of the variable region of the heavy chain of the monoclonal antibody is as shown in the amino acid sequence of positions 1 to 117 of SEQ ID NO.1, the amino acid sequence of the light chain variable region of the monoclonal antibody is as shown in the amino acid sequence of positions 1 to 108 of SEQ ID NO.3, the amino acid sequence of the heavy chain variable region of the single-chain antibody is as shown in the amino acid sequence of positions 462 to 586 of SEQ ID NO.1, and the amino acid sequence of the light chain variable region of the single-chain antibody is as shown in the amino acid sequence of positions 601 to 707 of SEQ ID NO.1.

[0012] In a more preferred embodiment, the constant region amino acid sequence of the monoclonal antibody heavy chain is as shown in the amino acid sequence of positions 118-447 of SEQID NO.1, and the constant region amino acid sequence of the monoclonal antibody light chain is as shown in the amino acid sequence of positions 109-214 of SEQID NO.3.

[0013] In a particularly preferred embodiment, the monoclonal antibody heavy chain and the single-chain antibody, and / or the heavy chain variable region of the single-chain antibody and the light chain variable region of the single-chain antibody are connected by a flexible linker peptide. The flexible linker peptide of the present invention generally comprises small amino acids, non-polar such as Gly, and polar such as Ser. These smaller amino acids provide flexibility of the linker peptide, allowing the two connected proteins to have a certain activity. In addition, the addition of Ser can form hydrogen bonds between the linker peptide and water molecules, giving the linker peptide stability in aqueous solution, thereby reducing the interaction between the linker peptide and the two proteins before and after. The most important flexible linker peptide at present is composed of Gly and Ser residues ("GS" linker). The sequence of the most widely used flexible linker peptide is (Gly-Gly-Gly-Gly-Ser) n. By adjusting the value of n (number of repetitions), the length of the GS linker peptide can be changed, so that the two connected proteins can be optimally separated or allowed to interact.

[0014] In a specific embodiment of the present invention, the amino acid sequence of the flexible connecting peptide is as shown in the amino acid sequence at positions 448-461, that is, GGGGSGGGGSGGGG.

[0015] In a specific embodiment of the present invention, the amino acid sequence of the polypeptide chain is shown in SEQ ID NO.1, and the amino acid sequence of the monoclonal antibody light chain is shown in SEQ ID NO.3. The bispecific antibody is defined as "4B6-H-4D12" in the present invention. The present invention constructs a bispecific antibody in the form of IgG-(scFv)2, that is, a single-chain antibody (scFv) is connected to the C-terminus of the Fc functional region of a normal IgG antibody molecule, and the CDR regions at both ends of the molecule bind to the target molecule to achieve bifunctionality.

[0016] Secondly, the present invention provides a polynucleotide encoding the above-mentioned bispecific antibody. In a specific embodiment of the present invention, the sequence of the polynucleotide of the polypeptide chain is shown in SEQ ID NO. 2, and the sequence of the polynucleotide of the monoclonal antibody light chain is shown in SEQ ID NO. 4. Those skilled in the art can reasonably expect that, without changing the amino acid sequence, the coding sequence can be appropriately optimized to facilitate protein expression and purification, so other coding sequences of the above-mentioned bispecific antibody can also implement the bispecific antibody defined in the present invention.

[0017] Third, the present invention provides an expression vector containing the above polynucleotide. In a specific embodiment of the present invention, the expression vector is pcDNA3.4. Those skilled in the art can reasonably expect that other eukaryotic or prokaryotic expression vectors of the prior art can also be used for the expression of the bispecific antibody of the present invention.

[0018] Fourth, the present invention provides a host cell containing the above expression vector. In a specific embodiment of the present invention, the Expi293 expression system is used to express the bispecific antibody. Those skilled in the art can reasonably expect that other engineered cells in the prior art, such as CHO cells, can also be used for the expression of the bispecific antibody of the present invention.

[0019] Finally, the present invention provides the use of the above-mentioned bispecific antibody in the preparation of a drug for the treatment of novel coronavirus pneumonia.

[0020] The cross-binding activity identification of the present invention shows that the bispecific antibody 4B6-H-4D12 can cross-bind to the S-ECD proteins of BA.5, BA.4.6, BF.7, XBB, and XBB.1.5. Compared with the parent monoclonal antibody, the bispecific antibody 4B6-H-4D12 has a broader spectrum of binding activity.

[0021] IC of bispecific antibody 4B6-H-4D12 neutralizing BA.5 pseudovirus 50 The IC value for neutralizing BF.7 pseudovirus is 10 ng / mL. 50 The IC value for neutralizing XBB.1.5 pseudovirus is 7 ng / mL. 50 The IC value for neutralizing BQ.1.1 pseudovirus is 11 ng / mL. 50 The IC value for neutralizing CH.1.1 pseudovirus is 20 ng / mL. 50 The results showed that compared with the parental monoclonal antibody and cocktail strategy, the bispecific antibody 4B6-H-4D12 has a broader and more efficient neutralizing activity against the currently prevalent main Omicron subvariant pseudovirus.

[0022] The bispecific antibody provided by the present invention has a good affinity with the S antigen of the Omicron subvariant, making it possible to develop it into a specific drug for COVID-19. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] Figure 1 .Schematic diagram of the bispecific antibody structure of the present invention;

[0024] Figure 2 SDS-PAGE profile of bispecific antibody purification;

[0025] Figure 3 ELISA was used to detect the cross-binding activity of 4B6-H-4D12;

[0026] Figure 4 Binding kinetics curve of 4B6-H-4D12 and BA.5 S-ECD protein;

[0027] Figure 5 Binding kinetics of 4B6-H-4D12 and BF.7 S-ECD protein;

[0028] Figure 6 Binding kinetics of 4B6-H-4D12 and XBB S-ECD protein;

[0029] Figure 7 Binding kinetics of 4B6-H-4D12 and XBB.1.5 S-ECD protein;

[0030] Figure 8 Neutralizing activity of antibodies against BA.5 pseudovirus;

[0031] Fig. 9 Neutralizing activity of antibodies against BF.7 pseudovirus;

[0032] Fig.10 Neutralizing activity of antibodies against XBB.1.5 pseudovirus;

[0033] Fig.11 Neutralizing activity of antibodies against BQ.1.1 pseudovirus;

[0034] Fig.12 Neutralizing activity of antibodies against CH.1.1 pseudovirus. DETAILED DESCRIPTION

[0035] The present invention will be further described below in conjunction with specific embodiments, and the advantages and features of the present invention will become clearer as the description proceeds. However, these embodiments are merely exemplary and do not constitute any limitation on the scope of protection defined by the claims of the present invention.

[0036] Example 1. Construction of bispecific antibodies

[0037] In the early stage, we obtained fully human monoclonal antibodies H4B6 and H4D12 with excellent broad-spectrum neutralizing activity from the memory B cells of recombinant new coronavirus vaccine recipients through flow sorting-single-cell PCR technology. Both of them target the RBD domain of the S protein of SARS-CoV-2. Among them, H4D12 has a strong neutralizing effect on the wild type of new coronavirus and its Delta, BA.2, BA.2.75, BA.2.76 and other variants. 50 All of them are lower than 10 ng / mL (see Chinese patent application CN202211732654.4). H4B6 has a strong neutralizing effect on the recently popular Omicron subvariants such as BA.5, BA.4.6, and BF.7. IC 50 All are below 100 ng / mL (see Chinese patent application CN202211734994.0).

[0038] According to the literature, the VH and VL of H4D12 were connected using GGGGSGGGGSGGGG linker to construct the scFv of H4D12, and then the scFv of H4D12 was connected to the C-terminus of the H4B6 heavy chain using the same linker. The key map was constructed as follows: Xba I restriction site-GCCGCCACC-signal peptide- H4B6 VH+CH- linker- H4D12 VH- linker- H4D12 VL-stop codon- BamH I restriction site. The target sequence was synthesized and linked into the pcDNA3.4 expression vector through Xba I and BamH I. The gene synthesis and construction of the 4B6-H-4D12 heavy chain recombinant expression plasmid were completed by General Biotechnology (Anhui) Co., Ltd., and then the plasmid was co-transfected with the H4B6 light chain expression plasmid into Expi293F cells to express the 4B6-H-4D12 bispecific antibody. Figure 1 A schematic diagram of the structure of the bispecific antibody of the present invention is given, which is a bispecific antibody in the form of IgG-(scFv)2, that is, the single-chain antibody (scFv) derived from the parent monoclonal antibody H4D12 is connected to the C-terminus of the Fc functional region of the parent monoclonal antibody IgG antibody molecule H4B6 derived from the normal structure, and bispecific recognition is achieved by binding to the target molecule through the CDR regions at both ends of the molecule.

[0039] Example 2. Transient expression and affinity chromatography purification of bispecific antibodies

[0040] Using the Expi293 expression system, 50 μg of heavy chain and 50 μg of light chain were mixed and transfected into 100 mL of Expi 293F cells. The operation was carried out according to the instructions (ThermoFisher Scientific, A14635). The culture medium was harvested after 5-6 days. After centrifugation, about 30 mL of the supernatant was collected. A 5 mL pre-packed Protein G affinity column was used and balanced with 20 mM PBS before loading. The sample was injected after the conductivity reached the baseline. After loading, the column was washed with 20 mM PBS until the baseline was stable. The target protein was eluted with 0.1 M glycine buffer at pH 2.7 and the OD was 0. 280 After reaching the baseline, stop collecting.

[0041] Results: SDS-PAGE detection of the bispecific antibody purified by affinity chromatography, see Figure 2 Lanes 1, 2, and 3 are the bands of the pre-column, post-column, and eluate of 4B6-H-4D12, respectively. The protein sample can be reduced to two fragments of 75 kDa and 25 kDa by mercaptoethanol, which correspond to the theoretical molecular weights of the heavy chain and light chain of the antibody, respectively, which is in line with expectations. Lane M is a molecular weight marker.

[0042] Example 3. Identification of cross-binding activity of bispecific antibodies

[0043] 1. Coating: One day before the experiment, dilute the Omicron subvariant BA.5 S-ECD antigen (Acro, SPN-C5229), BA.4.6 S-ECD antigen (Acro, SPN-C522m), BF.7 S-ECD antigen (Acro, SPN-C522q), XBB S-ECD antigen (Acro, SPN-C5248) and XBB.1.5 antigen (Acro, SPN-C524i) to 2 μg / mL with coating solution, coat the 96-well ELISA plate, 100 μL per well, and coat overnight at 4°C.

[0044] 2. Blocking: Wash three times using a plate washer (BIO-TEK, 405_LS), add 100 µL of blocking solution to each well, and incubate at 37°C for 1 hour.

[0045] 3. Sample incubation: Wash the plate 3 times. Add 100 μL of diluent to each well except the first well. Dilute the antibody to 4 μg / mL in the first well. Perform 4-fold gradient dilution at 100 μL / well. Set up three replicate wells for each antibody and incubate at 37°C for 1 h.

[0046] 4. Secondary antibody incubation: Wash the plate three times, dilute the HPR-labeled goat anti-human IgG secondary antibody (Abcam, ab97225) at 1:10000 with diluent, add 100 µL per well to the corresponding wells of the ELISA plate, and incubate at 37°C for 1 h.

[0047] 5. Color development: Wash the plate three times, add 100 µL of TMB single-component color development solution to each well, develop for 6 min at room temperature in the dark, then add 50 µL of stop solution to each well to terminate the reaction.

[0048] 6. Detect the OD value at 450-630 nm on an ELISA instrument, draw the curve using the Logistic four-parameter fitting method, and calculate the EC value of the antibody. 50 value.

[0049] Results: The binding activity of the bispecific antibody to the Omicron subvariant S protein was shown in Figure 3 4B6-H-4D12 can bind strongly to the S-ECD proteins of BA.5, BA.4.6, BF.7, XBB, and XBB.1.5. 50They were 56 ng / mL, 37 ng / mL, 47 ng / mL, 128 ng / mL, and 85 ng / mL, respectively. Although the parental monoclonal antibody H4B6 could strongly bind to the S-ECD proteins of BA.5, BA.4.6, and BF.7, its binding activity to the subvariants XBB and XBB.1.5 was significantly reduced. This indicates that the bispecific antibody 4B6-H-4D12 can cross-bind to the S-ECD proteins of BA.5, BA.4.6, BF.7, XBB, and XBB.1.5, and has a broader spectrum of binding activity than the parental monoclonal antibody.

[0050] Example 4: Affinity identification of bispecific antibodies

[0051] 1. Prepare buffer: Running Buffer (PBS + 0.02% Tween 20 + 0.2% BSA), Regeneration buffer (10 mM Gly, pH 1.75).

[0052] 2. Sample preparation: dilute the antibody to 50 nM (7.5 μg / mL) with Running Buffer, dilute the antigen to 100, 50, 25, 12.5, 6.25, and 3.125 nM, and pipette 250 μL into the corresponding positions of the 96-well plate. The plate where the sample is located is plate A. Add the corresponding samples according to the design layout and place them on the tilted plate rack.

[0053] 3. Turn on the Gator instrument, open the data acquisition software, and select the program module after the instrument completes the self-test. Use tweezers to carefully remove the HFC (Anti-HIgG Fc) probe from the box and soak it in a 96-well plate to which 200 μL buffer has been added. Place the 96-well plate on a horizontal plate rack, with the probe on plate B.

[0054] 4. Select K Assay program for sample detection: Select K Assay in the main interface Assay Setup, set Time to 600 s, Shaker A Speed ​​to 400 rpm, and Shaker B Speed ​​to 1000 rpm in Basic Parameters; select sample type according to the experimental scheme of Baseline – Loading – Baseline – Association – Dissociation in Plate Set Up, and enter the sample information in the 96-well plate, including sample name and concentration; define the Position, Time, Speed ​​and Step Type of each step in Assay Steps, Step 1 is Baseline, Time is 60 s, Speed ​​is 1000 rpm, Step 2 is Loading, Time is 100 s, Speed ​​is 400 rpm, Step 3 is Baseline, Time is 60 s, Speed ​​is 1000 rpm, Step 4 is Association, Time is 300 s, Speed ​​is 1000 rpm, Step 5 is Dissociation, Time is 300 s, Speed ​​is 1000 rpm; click Start in Preview to start running the program.

[0055] 5. Result analysis: In the Results & Analysis module on the main interface, click New KAnalysis, and select the experiment to be analyzed in Experiment Selection; set Ref. Probe in Reference to define the control probe in the experiment, select the non-control well, click Edit Formula, select the multiple-minus-multiple operation mode, subtract the reference, and click Processed to display the processed data; in Binding Fitting, select Global in Fitting in Parameters, and click Binding Curve Fit to calculate the fitting curve; in Kinetic Analysis, select Binding Fitting Graph, click Calculate Kinetics to calculate and display the binding kinetic data ka, kd, and KD of the bispecific antibody 4B6-H-4D12 with different antigens.

[0056] result: Figure 4-7The affinity constants of 4B6-H-4D12 and S-ECD of BA.5, BF.7, XBB, and XBB.1.5 are shown in Figure 1. The results show that the affinity constants KD are 1.52, 1.63, 7.42, and 1.40 nM, respectively. The measured R 2 The values ​​were all above 99% (see Table 1). The results showed that the bispecific antibody had a good affinity with the S antigen of the Omicron subvariant, making it possible to develop it into a specific drug for COVID-19.

[0057] Table 1. Binding kinetics data of bispecific antibody 4B6-H-4D12 and different subvariants of S protein

[0058]

[0059] Example 5. Identification of pseudovirus neutralizing activity of bispecific antibodies

[0060] 1. Dilute the purified bispecific antibody in a 3-fold serial dilution from the initial concentration using the culture medium DMEM + 10% FBS, add to a 96-well culture plate, set up 3 replicate wells, and the volume is 50 μL / well; then add 50 μL of the pseudovirus suspension of the new coronavirus variant (the virus is diluted to an appropriate titer using DMEM + 10% FBS) to each well, mix thoroughly, set up a survival control (without virus and antibody) and a death control (only virus), and incubate in a 37°C 5% CO2 cell culture incubator for 1 h.

[0061] 2. HEK293T cells were digested with 0.25% trypsin and diluted to 2.5×10 5 The cells were inoculated into a 96-well cell culture plate at a concentration of 100 μL / well and cultured overnight in a 37°C 5% CO2 cell culture incubator.

[0062] 3. After 48 hours, discard 100 μL of cell culture supernatant, add 100 μL of colorimetric substrate, and incubate for 2 min in the dark. Pipette 150 μL and transfer to a 96-well white microplate, and read the Luciferase signal value using a Tecan Spark multi-function microplate reader.

[0063] 4. Calculate the antibody neutralization rate using [1- (sample-survival control group signal) / (death control group signal-survival control group signal)] × 100%, fit the curve using GraphPad Prism 8, and calculate the antibody IC 50 value.

[0064] result: Figure 8-12The curves of the pseudovirus neutralization activity of 4B6-H-4D12 against BA.5, BF.7, XBB.1.5, BQ.1.1 and CH.1.1 as a function of concentration, and the IC value of bispecific antibody 4B6-H-4D12 for neutralizing BA.5 50 The IC value for neutralizing BF.7 pseudovirus is 10 ng / mL. 50 The IC value for neutralizing XBB.1.5 pseudovirus is 7 ng / mL. 50 The IC value for neutralizing BQ.1.1 pseudovirus is 11 ng / mL. 50 The IC value for neutralizing CH.1.1 pseudovirus is 20 ng / mL. 50 The results showed that compared with the parental monoclonal antibody and cocktail strategy, the bispecific antibody 4B6-H-4D12 has a broader and more efficient neutralizing activity against the currently prevalent main Omicron subvariant pseudovirus.

Claims

1. A fully human bispecific antibody against the novel coronavirus SARS-CoV-2 variants BA.5, BF.7, XBB.1.5, BQ.1.1 or CH.1.1, characterized in that: The bispecific antibody is composed of two polypeptide chains and two monoclonal antibody light chains, wherein each polypeptide chain is formed by connecting a single-chain antibody in series at the C-terminus of a monoclonal antibody heavy chain Fc region, and the single-chain antibody is formed by a heavy chain variable region and a light chain variable region through a linker from the N-terminus to the C-terminus, and the monoclonal antibody heavy chain and the monoclonal antibody light chain are from the same parent monoclonal antibody, and the amino acid sequences of the variable regions CDR1, CDR2 and CDR3 of the monoclonal antibody heavy chain are as follows: CDR1 is shown at positions 26-33 of SEQ ID NO.1, CDR2 is shown at positions 51-57 of SEQ ID NO.1, and CDR3 is shown at positions 96-106 of SEQ ID NO.1; the amino acid sequences of the variable regions CDR1, CDR2 and CDR3 of the monoclonal antibody light chain are as follows: CDR1 is shown at positions 27-32 of SEQ ID NO.3, CDR2 is shown at positions 50-52 of SEQ ID NO.3, and CDR3 is shown at positions 96-106 of SEQ ID NO.

1. NO.3; the amino acid sequences of CDR1, CDR2 and CDR3 of the heavy chain variable region of the single-chain antibody are as follows: CDR1 is as shown at positions 487-494 of SEQ ID NO.1, CDR2 is as shown at positions 512-519 of SEQ ID NO.1, and CDR3 is as shown at positions 558-575 of SEQ ID NO.3; the amino acid sequences of CDR1, CDR2 and CDR3 of the light chain variable region of the single-chain antibody are as follows: CDR1 is as shown at positions 627-632 of SEQID NO.1, CDR2 is as shown at positions 650-652 of SEQ ID NO.1, and CDR3 is as shown at positions 689-696 of SEQ ID NO.

1.

2. The bispecific antibody according to claim 1, characterized in that The amino acid sequence of the variable region of the heavy chain of the monoclonal antibody is shown as positions 1-117 of SEQ ID NO.1, the amino acid sequence of the light chain variable region of the monoclonal antibody is shown as positions 1-108 of SEQ ID NO.3, the amino acid sequence of the heavy chain variable region of the single-chain antibody is shown as positions 462-586 of SEQ ID NO.1, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown as positions 601-707 of SEQ ID NO.

1.

3. The bispecific antibody according to claim 1, characterized in that The amino acid sequence of the constant region of the monoclonal antibody heavy chain is shown in positions 118-447 of SEQ ID NO.1, and the amino acid sequence of the constant region of the monoclonal antibody light chain is shown in positions 109-214 of SEQ ID NO.

3.

4. The bispecific antibody according to claim 3, characterized in that The monoclonal antibody heavy chain and the single-chain antibody, and / or the heavy chain variable region of the single-chain antibody and the light chain variable region of the single-chain antibody are connected by a flexible connecting peptide.

5. The bispecific antibody according to claim 4, characterized in that The amino acid sequence of the flexible connecting peptide is shown in positions 448-461 of SEQ ID NO.

1.

6. The bispecific antibody according to claim 5, characterized in that The amino acid sequence of the polypeptide chain is shown in SEQ ID NO.1, and the amino acid sequence of the monoclonal antibody light chain is shown in SEQ ID NO.

3.

7. A polynucleotide encoding the bispecific antibody according to claim 6, characterized in that: The sequence of the polynucleotide encoding the polypeptide chain is shown in SEQ ID NO.2, and the sequence of the polynucleotide encoding the monoclonal antibody light chain is shown in SEQ ID NO.

4.

8. An expression vector comprising the polynucleotide of claim 7.

9. A host cell containing the expression vector according to claim 8.

10. Use of the bispecific antibody according to any one of claims 1 to 6 in the preparation of a medicament for treating pneumonia caused by the new coronavirus SARS-CoV-2.